CNA Diagnostics has entered a 67 country licensing and distribution agreement of its upcoming animal diagnostic tests for Paratuberculosis in Dairy cattle ("Johne's Disease") and Bovine Respiratory Disease (“BRD”) in beef cattle.
Calgary, AB (PRWEB) - CNA Diagnostics Inc. (“CNAD”, the “Corporation” or the “Company”) is pleased to announce it has entered a major strategic distribution agreement with Laboratorios Maymó, S.A. (“Maymó”) of Barcelona, Spain.
This agreement will see Maymó as CNAD’s exclusive distributor for Paratuberculosis (“Johne’s”) and Bovine Respiratory Disease (“BRD”) animal diagnostic tests throughout 67 countries in Europe, the Middle East, and North Africa (the “Territories”). CNAD will earn a royalty based on net sales of Johne’s and BRD tests sold with in territories.
The following countries are included in the Territories of the agreement: Albania Austria, Belgium, Belarus, Bosnia and Herzegovina, Bulgaria, Cyprus, Croatia, Denmark, Czech Republic, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Ireland, Iceland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Montenegro, Norway, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, Afghanistan, Algeria, Armenia, Azerbaijan, Bahrain, Qatar, Egypt, Georgia, Iraq, Iran, Israel, Jordan, Kazakhstan, Kyrgyzstan, Kuwait, Lebanon, Libya, The United Arab Emirates, Morocco, Oman, Pakistan, Saudi Arabia, Syria, Tajikistan, Tunisia, Turkmenistan, Uzbekistan and Yemen.
Johne’s costs are estimated to exceed €2.0 billion annually in the Territories. Johne’s in the herd diminishes the lifetime productivity of a dairy cow in all stages of its lifecycle. Competitive diagnostic tests for Johne’s exist, however, they have a low ability to accurately identify an infected animal (Test sensitivity of 30-60%), resulting in a very high number of false negative tests and limiting usefulness.
BRD is one of the most economically important disease in the beef cattle industry and is estimated to cost the beef industry worldwide in excess of $4 billion USD annually. Exact figures for the Territories are not available. Mortality rates in feedlots range from 2% to 10%, and up to 60% of cattle show respiratory lesions. Medical costs attributed to the treatment of BRD are substantial and the disease also has a negative economic impact on carcass merit and meat quality.
CNAD expects to announce the results of its Johne’s diagnostic test in Q1 2018 and BRD diagnostic test in Q2 2018.
“We have a great confidence in this project, and we hope that it will be the beginning of a long and close collaboration,” Stated Marc Maymó, CEO, Labroatorios Maymó, S.A
About CNA Diagnostics Inc.:
CNAD is a molecular diagnostics company. The corporation has developed a proprietary diagnostic
platform and is developing novel markers for chronic diseases in humans, production animals, and pets,
which can be used for accurate, rapid and cost-effective testing using serum samples.
About Laboratorios Maymó, S.A.:
Maymó is a European Pharmaceutical Laboratory specializing in Animal Health. Company with over 85 years of history, developing, manufacturing and commercializing pharmaceutical products, additives and biocides for veterinary use.
The manufacturing plant is located in Barcelona (Spain) and complies with strict European GMP (Good Manufacturing Practices) standards, for the manufacture of medicines in injectable form (B-Lactams and non-B-Lactams), oral solutions, oral powders and medicated premixes (B-Lactams and non-B-Lactams).
Maymó products are commercialized in various countries in Europe, Latin America, the Middle East, Asia and North Africa, with the reputation of EU quality products.
View original release here: http://www.prweb.com/releases/2018/01/prweb15055103.htm